Danaher and PuraGene Enter Strategic Collaboration Focused on CGT

Economic Observer NetworkOn March 17, 2026, IDT (Integrated DNA Technologies), a brand under the Danaher Life Sciences platform, signed a strategic cooperation agreement with Precision Scientific, a new drug R&D platform in China. The two parties will carry out full-chain cooperation in the cell and gene therapy (CGT) field, focusing on gene editing tools and clinical translational safety evaluation. This collaboration aims to provide end-to-end solutions for innovative pharmaceutical companies, potentially strengthening Danaher's ecosystem in the life sciences sector.

Recent Stock Trends

In the past week (March 13 to 19, 2026), Danaher's stock price showed a volatile trend, with a cumulative increase of 1.44% and a fluctuation range of 6.18%. Specifically: it slightly increased by 0.57% on March 13 (closing at $187.32), rose by 2.17% on March 16 (closing at $191.39), increased by 2.00% on March 17 (closing at $195.21), fell by 1.90% on March 18 (closing at $191.50), and dropped by 1.33% on March 19 (closing at $188.95). In terms of trading volume, it reached $7.91 billion on March 18 (turnover rate 0.58%), indicating relatively high short-term capital activity; the trading volume fell back to $3.17 billion on March 19 (turnover rate 0.24%). During the same period, the U.S. stock market was under pressure (S&P 500 fell 1.29% in the last five days), while the life sciences sector slightly increased by 0.10%.

Institutional Viewpoint

As of March 19, 2026, institutions maintain a positive outlook on Danaher. The average target price from 21 institutions is $264.19, indicating potential upside compared to the current share price of $188.95. In the March 2026 institutional view, 85% of ratings are Buy or Outperform, with 15% Hold. Earnings forecasts indicate that Q1 2026 revenue is expected to reach $6.001 billion (a year-over-year increase of 7.70%), with earnings per share projected at $1.938 (a year-over-year increase of 19.11%), reflecting market expectations for a recovery in the life sciences business.

The above content is based on publicly available information and does not constitute investment advice.